Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ESPR -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (5)	6/21/2001 4:19:42 PM
From: RCMac	Read Replies (1) \| Respond to of 16

Robertson-Stephens starts coverage of ESPR: robertsonstephens.com Esperion Therapeutics, Inc. [NASDAQ: ESPR $6.31] 2001E EPS: ($1.25), New 2002E EPS: ($1.09), New Buy Steven Harr, Biotechnology Michael King, Biotechnology “ESPR is building the premier biotech company focused on HDL cholesterol,” said Harr and King. “While pharmaceutical companies have focused on lowering LDL cholesterol, the bad cholesterol, thought leaders and recent research have stressed the importance of raising HDL cholesterol and improving HDL function. The government recently issued guidelines for the management of cholesterol. These guidelines focus on the importance of moving beyond the established practice of lowering LDL cholesterol, recommending a new focus on HDL in managing patient cardiovascular risks. We expect significant advancement of ESPR’s pipeline over the next twelve months, including two INDs and Phase IIa results for LUV. The acceptance of the IND for the RLT peptide will be the next event for the company (2Q:01), while the results for LUV will be the major event for the company this year (4Q:01). ESPR management team has a substantial track record of success in developing cholesterol-modifying drug. CEO, Dr. Roger Newton, led the Warner-Lambert team that discovered and developed Lipitor, the multibillion-dollar blockbuster drug that dominates the statin market. With a technology valuation of just over $100 million and four product candidates in the clinic targeting the large cholesterol management market by 3Q:01, we view ESPR as a very compelling investment opportunity. We are assuming coverage with a Buy rating and establishing an $11 price target.”